MacroGenics is a leading biopharmaceutical company that specializes in developing and commercializing innovative monoclonal antibody-based therapeutics for the treatment of cancer. With a broad pipeline of investigational product candidates, MacroGenics is at the forefront of developing breakthrough biologics and life-changing medicines to fight cancer. They employ leading multispecific antibody technology platforms and protein engineering expertise to create innovative solutions for patients with unmet needs.

MacroGenics also offers fully-integrated, antibody-based development capabilities, including GMP manufacturing, ensuring the highest quality in their products. Their portfolio includes a range of potential therapies, such as MARGENZA®, MGC018, Lorigerlimab, Tebotelimab, MGD024, IMGC936, Enoblituzumab, Retifanlimab, and MGD014. Committed to making a difference in the lives of patients, MacroGenics conducts clinical trials and provides resources and guides to patients and caregivers.

With their focus on developing innovative medicines, MacroGenics aims to bring hope and improved outcomes to cancer patients worldwide